Ascendis Pharma AS (ASND) — Quality & forensics
As of 2026-09-23 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 27
- Quality 63
- Growth 75
- Balance sheet 31
- Cash quality 79
- Capital allocation 19
- Momentum 44
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the ASND chart & overview · the earnings record
FAQ · from the current data · as of 2026-09-23
Quick answers
What is Ascendis Pharma AS's Closelook quality reading?
The composite reads 51/100 across 7 modules, as of 2026-09-23: valuation 27, quality 63, growth 75, balance sheet 31, cash quality 79, capital allocation 19, momentum 44. Closelook scores are research diary readings, not ratings or investment advice.
What is Ascendis Pharma AS's Altman Z-Score?
3.71, which sits in the safe zone (above 2.99) as of 2026-09-23. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Ascendis Pharma AS's Piotroski F-Score?
5 of 9, as of 2026-09-23. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Ascendis Pharma AS's Beneish M-Score indicate?
-3.07 — below the −1.78 manipulation-risk threshold, as of 2026-09-23. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- ONC BeiGene, Ltd.industry
- CAI Caris Life Sciences, Inc. Common Stockindustry
- REGN Regeneron Pharmaceuticals Incindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- VKTX Viking Therapeutics Incindustry
- HALO Halozyme Therapeutics Incindustry
- DNA Ginkgo Bioworks Holdingsindustry
- RXRX Recursion Pharmaceuticals Incindustry
- SMMT Summit Therapeutics PLCindustry
- IBRX Immunitybio Incindustry
- GMAB Genmab ASindustry
- MRVI Maravai Lifesciences Holdings Incindustry
- TGTX TG Therapeutics Incindustry
- CRSP Crispr Therapeutics AGindustry
- EXEL Exelixis Incindustry